GNI Group Ltd.
Full Subsidiarization of Ayumi Pharmaceutical Holdings and Capital Partnership | June 2026
Executing the acquisition of all shares of Ayumi Pharmaceutical Holdings and issuing new shares through a third-party allotment to advance full subsidiarization and capital partnership. A significant capital policy involving approximately 4.7 billion yen of capital infusion and share transfer.
Key Figures
- Share acquisition cost: 44,776 million yen
- Number of new shares issued: 9,974,291 shares
- Fundraising amount: 26,770,997,044 yen
AI要約
Overview of Capital Policy
Based on a board resolution on June 5, 2026, the Company will acquire all shares of Ayumi Pharmaceutical Holdings for 44,776 million yen, advancing to full subsidiarization, and will issue new shares through a third-party allotment. The new shares will total 9,974,291, with an issue price of 2,684 yen per share. This will realize approximately 2.677 billion yen in capital raising, aiming to strengthen capital and expand business. The funds will be used for partial in-kind contribution of share transfer proceeds and are expected to contribute to future growth strategies.
Future Outlook and Impact on Shareholders
This capital policy aims to acquire Ayumi Pharmaceutical Holdings' commercial platform in Japan and accelerate overseas pipeline development and bio-similar expansion. Existing shareholders' ownership ratios will be diluted, but the objective is to enhance long-term corporate value and establish a stable earnings base. Fundraising will mainly be through third-party allotment, and it has been confirmed that there are no links to antisocial forces.
Kabusikigaisha Ga Group
Company overview · Stock price · Financial data · All IR
